应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02367 巨子生物
已收盘 07-03 16:08:13
43.100
-0.150
-0.35%
最高
44.200
最低
42.800
成交量
226.70万
今开
43.000
昨收
43.250
日振幅
3.24%
总市值
443.16亿
流通市值
443.16亿
总股本
10.28亿
成交额
9,830万
换手率
0.22%
流通股本
10.28亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
【券商聚焦】浦银国际维持巨子生物(02367)“买入”评级 料两大主力品牌在下半年延续增长势头
金吾财讯 · 13:33
【券商聚焦】浦银国际维持巨子生物(02367)“买入”评级 料两大主力品牌在下半年延续增长势头
【券商聚焦】国信证券维持巨子生物(02367)“优大于市”评级 指新品迭代放量有望推动化妆品业务增长
金吾财讯 · 07-02 17:03
【券商聚焦】国信证券维持巨子生物(02367)“优大于市”评级 指新品迭代放量有望推动化妆品业务增长
巨子生物07月02日遭主力抛售380万元 环比增加245.45%
自选股智能写手 · 07-02 16:15
巨子生物07月02日遭主力抛售380万元 环比增加245.45%
巨子生物(02367)下跌5.02%,报43.55元/股
金融界 · 07-02 10:22
巨子生物(02367)下跌5.02%,报43.55元/股
国信证券:维持巨子生物(02367)“优大于市”评级 618大促表现持续亮眼
智通财经 · 07-01 13:45
国信证券:维持巨子生物(02367)“优大于市”评级 618大促表现持续亮眼
巨子生物股价涨超3% 花旗首予“买入”评级
新浪港股 · 06-28
巨子生物股价涨超3% 花旗首予“买入”评级
港股异动 | 巨子生物(02367)涨逾3% 花旗预计上半年净利润将增加 公司旗下两大核心品牌均实现逆势高增
智通财经 · 06-28
港股异动 | 巨子生物(02367)涨逾3% 花旗预计上半年净利润将增加 公司旗下两大核心品牌均实现逆势高增
港股概念追踪 |日韩品牌份额被挤压 化妆品国货品牌份额将持续提升(附概念股)
智通财经 · 06-28
港股概念追踪 |日韩品牌份额被挤压 化妆品国货品牌份额将持续提升(附概念股)
花旗:巨子生物(02367)将成为“护肤医疗化”结构性趋势的主要受益者 首予“买入”评级
智通财经 · 06-27
花旗:巨子生物(02367)将成为“护肤医疗化”结构性趋势的主要受益者 首予“买入”评级
巨子生物6月26日遭南向资金减持291.72万股
自选股智能写手 · 06-27
巨子生物6月26日遭南向资金减持291.72万股
巨子生物06月26日主力资金流入543万元 连续3日加仓
自选股智能写手 · 06-26
巨子生物06月26日主力资金流入543万元 连续3日加仓
【券商聚焦】中信证券指618美妆客单价走低 “焦点” 分散化
金吾财讯 · 06-26
【券商聚焦】中信证券指618美妆客单价走低 “焦点” 分散化
研报掘金|中金:上调巨子生物目标价至57港元 未来增长前景具可预见性
格隆汇资讯 · 06-26
研报掘金|中金:上调巨子生物目标价至57港元 未来增长前景具可预见性
《大行》中金升巨子生物(02367.HK)目标价至57元 上调全年盈测
阿斯达克财经 · 06-26
《大行》中金升巨子生物(02367.HK)目标价至57元 上调全年盈测
德邦证券:维持巨子生物(02367)“买入”评级 上调2024年业绩预期
智通财经 · 06-25
德邦证券:维持巨子生物(02367)“买入”评级 上调2024年业绩预期
巨子生物盘中涨7% 中金料公司全年业绩有望超此前预期
金融界 · 06-25
巨子生物盘中涨7% 中金料公司全年业绩有望超此前预期
中金:维持巨子生物(02367)“跑赢行业”评级 目标价升至57港元
智通财经 · 06-25
中金:维持巨子生物(02367)“跑赢行业”评级 目标价升至57港元
【港股通】巨子生物(02367)涨3.69% “618”大促可复美与可丽金GMV同比大增
金吾资讯 · 06-25
【港股通】巨子生物(02367)涨3.69% “618”大促可复美与可丽金GMV同比大增
巨子生物早盘涨逾5% 可复美线上GMV同比增长超60%
新浪港股 · 06-25
巨子生物早盘涨逾5% 可复美线上GMV同比增长超60%
港股异动 | 巨子生物(02367)涨超4% 双品牌全渠道延续高增长 可复美线上GMV同比增长超60%
智通财经 · 06-25
港股异动 | 巨子生物(02367)涨超4% 双品牌全渠道延续高增长 可复美线上GMV同比增长超60%
加载更多
公司概况
公司名称:
巨子生物
所属市场:
SEHK
上市日期:
--
主营业务:
巨子生物控股有限公司是一家中国的投资控股公司。该公司通过其子公司主要从事基于生物活性材料的美容和健康产品的研发、生产和销售。该公司的主要产品包括功能性护肤品和医用敷料,其产品的关键生物活性成分为重组胶原蛋白。该公司还开发和生产基于人参皂苷技术的稀有功能食品。该公司主要在国内市场开展其业务。
发行价格:
--
{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":43.1,"timestamp":1719994093015,"preClose":43.25,"halted":0,"volume":2267034,"delay":0,"floatShares":1028220000,"shares":1028220000,"eps":1.5895268,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.15,"latestTime":"07-03 16:08:13","open":43,"high":44.2,"low":42.8,"amount":98301962,"amplitude":0.03237,"askPrice":43.2,"askSize":800,"bidPrice":43.1,"bidSize":25400,"shortable":3,"etf":0,"ttmEps":1.5820132745972721,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720056600000},"adr":0,"listingDate":1667491200000,"adjPreClose":43.25,"dividendRate":0.010917,"openAndCloseTimeList":[[1719970200000,1719979200000],[1719982800000,1719993600000]],"volumeRatio":0.685545,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"2448983125","title":"【券商聚焦】浦银国际维持巨子生物(02367)“买入”评级 料两大主力品牌在下半年延续增长势头","url":"https://stock-news.laohu8.com/highlight/detail?id=2448983125","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448983125?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:33","pubTimestamp":1719984816,"startTime":"0","endTime":"0","summary":"金吾财讯 | 浦银国际发研报指,巨子生物 旗下可复美品牌和可丽金品牌在618全周期线上全渠道GMV分别同比增长60%+和100%+,可复美品牌在天猫和抖音渠道均位列护肤品前十榜单中。该行预测在618大促高增速的驱动下,公司上调2024年全年业绩指引。该行认为,基于两大核心品牌在更为完善的线上布局以及可丽金品牌赋予的第二增长动力的成效,公司在618期间实现高增长,有望在2024年下半年延续增长势头。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200915/N2I1NTQ1N2YyMmRiZjBmNTUwMDA0Njc2Mzg1.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/N2I1NTQ1N2YyMmRiZjBmNTUwMDA0Njc2Mzg1.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939680","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"gpt_icon":0},{"id":"2448138895","title":"【券商聚焦】国信证券维持巨子生物(02367)“优大于市”评级 指新品迭代放量有望推动化妆品业务增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2448138895","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448138895?lang=zh_cn&edition=full","pubTime":"2024-07-02 17:03","pubTimestamp":1719911023,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国信证券发表研报,巨子生物 公布618大促期间旗下品牌表现情况,其中可复美线上全渠道全周期GMV同比增长60%+,可丽金线上全渠道全周期GMV同比增长100%+。该行指,依托前期在胶原蛋白赛道多年积累赋能产业化快速发展,公司目前已建立了较为深厚的重组胶原蛋白品牌心智,本次618大促双品牌持续亮眼表现也印证公司强大品牌势能,后续新品的持续迭代放量也有望带动化妆品业务的稳健增长。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/NjMyMjE5OTk0MjExOTc0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/NjMyMjE5OTk0MjExOTc0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939621","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002736","02367"],"gpt_icon":0},{"id":"2448184516","title":"巨子生物07月02日遭主力抛售380万元 环比增加245.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448184516","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448184516?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:15","pubTimestamp":1719908158,"startTime":"0","endTime":"0","summary":"07月02日, 巨子生物股价跌5.67%,报收43.25元,成交金额1.23亿元,换手率0.27%,振幅8.40%,量比0.60。巨子生物今日主力资金净流出380万元,上一交易日主力净流出110万元,今日环比增加245.45%。该股近5个交易日上涨0.35%,主力资金累计净流入1429万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入936万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702161613956523dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702161613956523dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","BK1207"],"gpt_icon":0},{"id":"2448974097","title":"巨子生物(02367)下跌5.02%,报43.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448974097","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448974097?lang=zh_cn&edition=full","pubTime":"2024-07-02 10:22","pubTimestamp":1719886948,"startTime":"0","endTime":"0","summary":"7月2日,巨子生物(02367)盘中下跌5.02%,截至10:22,报43.55元/股,成交2474.13万元。巨子生物控股有限公司是一家专注于研发和生产重组胶原蛋白和稀有人参皂苷的高科技企业,主要业务包括功效性护肤品、医疗器械、功能性食品及特殊医学用途配方食品。公司拥有79项专利及专利申请,其重组胶原蛋白技术在中国获得行业内首个专利授权,并在2013年和2016年分别获得国家技术发明奖二等奖和中国专利金奖。截至2023年年报,巨子生物营业总收入35.24亿元、净利润14.52亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/02102241316597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1207","02367"],"gpt_icon":0},{"id":"2448895930","title":"国信证券:维持巨子生物(02367)“优大于市”评级 618大促表现持续亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2448895930","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448895930?lang=zh_cn&edition=full","pubTime":"2024-07-01 13:45","pubTimestamp":1719812726,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,国信证券发布研究报告称,维持巨子生物“优大于市”评级,考虑到618大促表现优异,以及新品持续迭代带动公司全年业绩上行,上调2024-2026年归母净利润至18.37/23.18/27.78亿元。整体来看,依托胶原蛋白赛道的红利期,以及公司作为龙头的先发优势,公司今年618大促表现仍持续亮眼,同时今年大促公司整体退货率保持稳定,整体有望夯实公司中报业绩表现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002736","02367"],"gpt_icon":0},{"id":"2446510961","title":"巨子生物股价涨超3% 花旗首予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446510961","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446510961?lang=zh_cn&edition=full","pubTime":"2024-06-28 10:35","pubTimestamp":1719542123,"startTime":"0","endTime":"0","summary":"巨子生物(02367)股价上涨3.30%,现报45.40港元,成交额3684.56万港元。\n 花旗发布研究报告称,首予巨子生物“买入”评级,称其将成为“护肤医疗化”结构性趋势的主要受益者。预计2024年上半年净利润将增加35%,2023-26年复合年增长率将达26%。报告指出,尽管整体化妆品需求放缓,但鉴于年轻消费者不断增长的需求,预计皮肤美容护理品将继续蓬勃发展。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-28/doc-incaheis6199043.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-28/doc-incaheis6199043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["02367"],"gpt_icon":0},{"id":"2446651272","title":"港股异动 | 巨子生物(02367)涨逾3% 花旗预计上半年净利润将增加 公司旗下两大核心品牌均实现逆势高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2446651272","media":"智通财经","labels":["viewpoints"],"top":-1,"share":"https://www.laohu8.com/m/news/2446651272?lang=zh_cn&edition=full","pubTime":"2024-06-28 10:15","pubTimestamp":1719540901,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,巨子生物涨逾3%,截至发稿,涨3.07%,报45.30港元,成交额1487.86万港元。预计2024年上半年净利润将增加35%,2023-26年复合年增长率将达26%。此前,据巨子生物官方微信公众号公布618战报,2024年618全周期可复美线上全渠道GMV同比增长60%+,可丽金线上全渠道GMV同比增长100%+,公司旗下两大核心品牌均实现逆势高增。本土、国际公司加速重组胶原蛋白领域布局,持续推出新品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07226","02367","HSCEI","HSTECH","YANG"],"gpt_icon":0},{"id":"2446395511","title":"港股概念追踪 |日韩品牌份额被挤压 化妆品国货品牌份额将持续提升(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2446395511","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446395511?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:31","pubTimestamp":1719538267,"startTime":"0","endTime":"0","summary":"兴业证券研报指出,化妆品行业整体增速放缓,但格局变化比预想更剧烈,国货品牌份额将持续提升,日系韩系品牌再卷土重来的概率较低。线上流量成本提高,直播电商流量下滑,渠道固化,行业增速放缓;国货品牌市占率有所提升,挤占部分日系、韩系品牌份额,国货品牌打造大单品的策略已经日趋成熟。近年来公司推出子品牌同时,积极对主品牌焕新升级,2023年主品牌韩束抖音渠道放量明显,驱动2023年营收与利润双升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","BK1161","02145","06826","BK1207","HSTECH","07226","BK1593","YANG","HSCEI"],"gpt_icon":0},{"id":"2446851305","title":"花旗:巨子生物(02367)将成为“护肤医疗化”结构性趋势的主要受益者 首予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446851305","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446851305?lang=zh_cn&edition=full","pubTime":"2024-06-27 13:55","pubTimestamp":1719467743,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,花旗发布研究报告称,首予巨子生物(02367)“买入”评级,称其将成为“护肤医疗化”结构性趋势的主要受益者。预计2024年上半年净利润将增加35%,2023-26年复合年增长率将达26%。报告指出,尽管整体化妆品需求放缓,但鉴于年轻消费者不断增长的需求,预计皮肤美容护理品将继续蓬勃发展。该行看好的中国化妆品企业依次为珀莱雅(603605.SH)、巨子生物及贝泰妮(300975.SZ)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","159891"],"gpt_icon":0},{"id":"2446708324","title":"巨子生物6月26日遭南向资金减持291.72万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446708324","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446708324?lang=zh_cn&edition=full","pubTime":"2024-06-27 09:31","pubTimestamp":1719451897,"startTime":"0","endTime":"0","summary":"6月26日,南向资金减持巨子生物291.72万股。截止当日收盘,港股通共持有巨子生物16061.93万股,占流通股15.61%。巨子生物近5个交易日下跌5.22%,港股通累计减持229.27万股;近20个交易日下跌6.97%,港股通累计减持474.98万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062709414795dc3cd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062709414795dc3cd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","02367"],"gpt_icon":0},{"id":"2446356103","title":"巨子生物06月26日主力资金流入543万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2446356103","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446356103?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:15","pubTimestamp":1719389752,"startTime":"0","endTime":"0","summary":"06月26日, 巨子生物股价涨0.78%,报收45.35元,成交金额8290万元,换手率0.18%,振幅2.22%,量比0.36。巨子生物今日主力资金净流入543万元,连续3日净流入,上一交易日主力净流入1326万元,今日环比减少59.05%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为64.29%,平均涨幅为1.62%。该股近5个交易日下跌4.91%,主力资金累计净流入3961万元;近20日主力资金累计净流入1119万元,其中净流入天数为10日。该股主力净额占比0.01%,港股市场排名206/2634。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062616162595d98da9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062616162595d98da9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","02367"],"gpt_icon":0},{"id":"2446337982","title":"【券商聚焦】中信证券指618美妆客单价走低 “焦点” 分散化","url":"https://stock-news.laohu8.com/highlight/detail?id=2446337982","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446337982?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:12","pubTimestamp":1719385930,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券表示,618美妆客单价走低,“焦点”分散化。价格仍为重要竞争维度:品牌主战场淘系客单价走低,抖音加码低价、倾斜投流,性价比平台拼多多增速突出。“焦点”分散化,关注其带来的营销打法变化:淘宝取消预售、抖音调整算法,推动头部达人带货分散化,从结果看部分头部品牌产品集中度降低,“大单品时代”逐步向“矩阵化时代”过渡。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/ZjFkNmRhNDdmNGNlNWE2NWI4ZjM1ZDNmNTg4YjM5OTg4NDI0NTU0Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/ZjFkNmRhNDdmNGNlNWE2NWI4ZjM1ZDNmNTg4YjM5OTg4NDI0NTU0Nw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","600030","BK1207","BK0012","LU0405327148.USD","LU2148510915.USD","LU1328615791.USD","02367","LU1794554557.SGD","BK0028","06030","LU1064130708.USD","LU1720050803.USD","LU1064131003.USD","BK0196","BK1516","LU0405327494.USD","BK0183","LU1997245177.USD","BK1521","LU1997245094.SGD","BK1564","02145","BK0188","BK1147"],"gpt_icon":0},{"id":"2446814334","title":"研报掘金|中金:上调巨子生物目标价至57港元 未来增长前景具可预见性","url":"https://stock-news.laohu8.com/highlight/detail?id=2446814334","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446814334?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:34","pubTimestamp":1719383656,"startTime":"0","endTime":"0","summary":"中金发表研究报告指,巨子生物今年5月15日至6月20日举行的618促销活动期间节,可复美(Comfy)及可丽金(Collagen)两大品牌在各大电商平台线上商品成交总额(GMV)分别按年增长超过60%和100%,预期将为第二季业绩奠定良好基础,相应将今明两年经调整盈利预测分别上调5% ,至19.2亿及22.8亿元。中金指出,巨子生物是中国内地重组胶原蛋白领域的领军企业,对其发展前景保持乐观看法,认为未来增长前景具可预见性,维持“跑赢行业”评级,并将目标价上调7.5%至57港元,对应今明两年预测市盈率约28倍和23倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062614342695d92cc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062614342695d92cc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367"],"gpt_icon":0},{"id":"2446387031","title":"《大行》中金升巨子生物(02367.HK)目标价至57元 上调全年盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2446387031","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446387031?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:50","pubTimestamp":1719373800,"startTime":"0","endTime":"0","summary":"中金指出,巨子生物是中国内地重组胶原蛋白领域的领军企业,对其发展前景保持乐观看法,认为未来增长前景具可预见性,维持“跑赢行业”评级,并将目标价上调7.5%至57元,对应今明两年预测市盈率约28倍和23倍。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20221209170600402_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20221209170600402_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359295/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02367"],"gpt_icon":0},{"id":"2446894559","title":"德邦证券:维持巨子生物(02367)“买入”评级 上调2024年业绩预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2446894559","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446894559?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:48","pubTimestamp":1719305288,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,德邦证券发布研究报告称,维持巨子生物“买入”评级,基于公司618大促的动销数据,上调24-26年营收至48.83/62.76/77.67亿元,上调净利润至18.94/24.22/30.1亿,同比增速为30%/28%/24%。德邦证券主要观点如下:618大促结束,巨子生物两大品牌高增长,夯实品牌力。可丽金:线上全渠道全周期GMV同增100%+,其中天猫同增70%+、抖音同增300%+、京东同增200%+、唯品会同增170%+,品牌转型取得成效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","161027"],"gpt_icon":0},{"id":"2446085095","title":"巨子生物盘中涨7% 中金料公司全年业绩有望超此前预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2446085095","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446085095?lang=zh_cn&edition=full","pubTime":"2024-06-25 11:42","pubTimestamp":1719286930,"startTime":"0","endTime":"0","summary":"巨子生物(2367.HK)盘中一度涨至7%,现报45.45港元,总市值467亿港元。中金报告称,基于618高增表现,料巨子生物全年业绩有望超此前预期,上调24-25年经调整净利润预测5%/5%至19.2/22.8亿元。维持“跑赢行业”评级,上调目标价7.5%至57港元。公司618大促期间(5.15-6.20)可复美、可丽金线上全渠道GMV分别同增60%+/100%+,多款明星单品销售额于细分品类排名领先,品牌势能持续释放,该行认为有望为Q2业绩奠定坚实基础,重申看好其作为重组胶原蛋白龙头的广阔成长空间,并上调全年业绩预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062511452995d4ee71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062511452995d4ee71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","02367"],"gpt_icon":0},{"id":"2446855829","title":"中金:维持巨子生物(02367)“跑赢行业”评级 目标价升至57港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446855829","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446855829?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:43","pubTimestamp":1719279838,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中金发布研究报告称,基于618高增表现,料巨子生物全年业绩有望超此前预期,上调24-25年经调整净利润预测5%/5%至19.2/22.8亿元。维持“跑赢行业”评级,上调目标价7.5%至57港元。中金主要观点如下:1、可复美、可丽金618增势亮眼,奠定Q2业绩高增基础。两大品牌显著跑赢美妆大盘,行业份额进一步提升,该行认为有望为Q2业绩奠定坚实基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"gpt_icon":0},{"id":"2446858135","title":"【港股通】巨子生物(02367)涨3.69% “618”大促可复美与可丽金GMV同比大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2446858135","media":"金吾资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446858135?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:41","pubTimestamp":1719279663,"startTime":"0","endTime":"0","summary":"金吾财讯 | 巨子生物 股价反弹回升,暂报45港元,涨3.69%,成交额3155.47万港元。消息面上,招银国际表示,巨子生物“618”期间,可复美线上GMV同比增长超60%,可丽金线上GMV同比增长超100%。该行继续看好巨子生物护肤品类线上销售的持续增长,预期注射类胶原蛋白产品在年内获批。基于DCF模型,维持目标价60.83港元,维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406250941419f61edc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406250941419f61edc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","BK1207","02367","07226","HSCEI"],"gpt_icon":0},{"id":"2446683042","title":"巨子生物早盘涨逾5% 可复美线上GMV同比增长超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446683042","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446683042?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:40","pubTimestamp":1719279600,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 巨子生物(02367)早盘上涨4.72%,现报45.45港元,成交额3307.72万港元。\n 近日,巨子生物公布“618”战报,2024年“618”期间(5月15日至6月20日),可复美线上GMV同比增长超60%,可丽金线上GMV同比增长超100%。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-25/doc-inazxaqt7219205.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-25/doc-inazxaqt7219205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1207","02367"],"gpt_icon":0},{"id":"2446830985","title":"港股异动 | 巨子生物(02367)涨超4% 双品牌全渠道延续高增长 可复美线上GMV同比增长超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446830985","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446830985?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:33","pubTimestamp":1719279213,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,巨子生物(02367)涨超4%,截至发稿,涨4.38%,报45.30港元,成交额2203.87万港元。消息面上,近日,巨子生物公布“618”战报,2024年“618”期间(5月15日至6月20日),可复美线上GMV同比增长超60%,可丽金线上GMV同比增长超100%。根据魔镜统计,可复美在天猫淘宝、京东和抖音的1-5月GMV合计达到15.8亿元,同比增长123%。得益于核心大单品胶原棒以及新品焦点面霜的放量,可复美的面部精华和乳液/面霜品类在天猫淘宝平台的1-5月GMV分别同比增长289%和385%,引领可复美品牌的整体增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","BK1207","HSCEI","07226","02367","YANG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":-0.0389},{"period":"1month","weight":-0.1073},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.3118},{"period":"1year","weight":0.263},{"period":"ytd","weight":0.24}],"compareEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0624},{"period":"6month","weight":0.0675},{"period":"1year","weight":-0.0796},{"period":"ytd","weight":0.0423}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家中国的投资控股公司。该公司通过其子公司主要从事基于生物活性材料的美容和健康产品的研发、生产和销售。该公司的主要产品包括功能性护肤品和医用敷料,其产品的关键生物活性成分为重组胶原蛋白。该公司还开发和生产基于人参皂苷技术的稀有功能食品。该公司主要在国内市场开展其业务。","exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}